Next-Generation Therapeutic Strategies for Relapsed/Refractory Multiple Myeloma: Targeting BCMA

How I am using currently approved anti-BCMA agents as a part of the treatment plan for patients with R/R MM.

Sagar Lonial, MD Released: September 9, 2021

Experts answer frequently asked questions on the management of relapsed or refractory multiple myeloma with BCMA-targeted agents.

Sagar Lonial, MD
Program Director Suzanne Lentzsch, MD, PhD Thomas G. Martin, MD Released: October 29, 2021

Download this slideset based on the content from a live stream CCO webinar from Sagar Lonial, MD, on optimal use of anti-BMCA antibody–drug conjugates for patients with relapsed/refractory multiple myeloma.

Sagar Lonial, MD Released: September 10, 2021

Download this slideset based on the content from a live stream CCO webinar from Thomas G. Martin, MD, on how to integrate CAR T-cell therapy for patients with relapsed/refractory multiple myeloma.

Thomas G. Martin, MD Released: September 10, 2021

Download this slideset based on the content from a live stream CCO webinar from Suzanne Lentzsch, MD, PhD, on the latest data on BCMA x CD3 bispecific molecules for patients with relapsed/refractory multiple myeloma.

Suzanne Lentzsch, MD, PhD Released: September 10, 2021

Gain key clinical insights fast, with this short slideset from CCO on key considerations for optimal use of anti-BMCA therapy for patients with relapsed/refractory multiple myeloma.

Suzanne Lentzsch, MD, PhD Sagar Lonial, MD Thomas G. Martin, MD Released: October 5, 2021

On-demand webcast of a CCO live webinar on the use of BCMA-targeted agents in relapsed/refractory multiple myeloma.

Sagar Lonial, MD
Program Director Suzanne Lentzsch, MD, PhD Thomas G. Martin, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits™ Released: October 15, 2021 Expired: No longer available for credit